Befrena launches for treatment of allergic dermatitis in dogs

In a recent press release, Elanco announced the launch of Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody for the treatment of allergic dermatitis in dogs. This injectable joins Cytopoint (lokivetmab) by Zoetis Petcare as the second monoclonal antibody treatment for canine allergic itch in the U.S. 

According to Elanco, Befrena “starts controlling allergic itch within 24 hours” and “offers at least 6 to 8 weeks of itch relief.” It is meant to be given in the veterinary hospital by or under the supervision of a licensed veterinarian. There are no age or weight restrictions to its use.  

Befrena comes in four different vial sizes that vary in the volume of product they contain from 0.5 mL to 2.0 mL, which can be combined as needed to appropriately dose a patient by their weight.  This differs from Cytopoint, where all vial options contain 1.0 mL of product in varying concentrations.  

The USDA approved Befrena in December 2025. Some veterinarians have already had access to the monoclonal antibody via the Befrena Early Experience Program and have reported “positive results,” according to Elanco. 

Commonly reported side effects during clinical studies included dermatitis and pyoderma, which were also reported in the placebo group.  

The safety data for Befrena also highlighted that monoclonal antibodies can induce anti-drug antibodies that may reduce a patient’s response to treatment and/or elicit immune-mediated adverse reactions. 

Photo credit: chris-mueller/iStock via Getty Images Plus 

Disclaimer: Trends™ content is meant to inform, educate, and inspire by providing an array of diverse viewpoints. Any content published should not be viewed as an official stance, position, or endorsement by the American Animal Hospital Association (AAHA) or its Board of Directors.